Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Trinity Biotech’s FDA submissions, R&D milestones, and global kit sales can be tough—each new 10-K or 8-K piles pages of biotech terminology on top of complex accounting notes. If you have ever wondered “How do I decode a Trinity Biotech annual report 10-K simplified?” or searched for “Trinity Biotech insider trading Form 4 transactions,” you already know the challenge.
Stock Titan solves it. Our AI models break down every Trinity Biotech quarterly earnings report 10-Q filing, highlight segment revenue from infectious-disease kits, and flag changes in diabetes management initiatives. Need real-time alerts? Receive “Trinity Biotech Form 4 insider transactions real-time” updates the moment executives trade. Our platform also provides concise explanations of Form DEF 14A so you can quickly grasp “Trinity Biotech proxy statement executive compensation” without digging through compensation tables.
Explore every disclosure in one place: 10-K audits of global manufacturing risks, 8-K material events explained when FDA clearances arrive, and “Trinity Biotech earnings report filing analysis” that connects R&D spending to pipeline progress. Use our AI-powered summaries—built for understanding Trinity Biotech SEC documents with AI—to compare quarter-over-quarter HbA1c kit sales, monitor “Trinity Biotech executive stock transactions Form 4,” and capture red-flags hidden deep in footnotes. Whether you type “Where can I find Trinity Biotech quarterly earnings report 10-Q filing?” or “Trinity Biotech SEC filings explained simply,” this page delivers accurate data, plain-language insights, and the confidence to act on them.
Trinity Biotech plc filed a Form 6-K to report that, on November 18, 2025, it issued a press release announcing a major regulatory approval related to manufacturing of its Uni-Gold rapid HIV test. The approval covers offshored and outsourced production of this market-leading diagnostic product.
The company describes this step as part of a broader effort to transform its financial performance, suggesting that the new manufacturing structure is intended to support that strategy. Details of the approval and its expected impact are contained in the press release attached as Exhibit 99.1.
Trinity Biotech plc submitted a Form 6-K to report a corporate update related to its EpiCapture prostate cancer testing technology. The company states that on November 14, 2025 it issued a press release announcing a collaboration to advance epigenetic analysis for its EpiCapture prostate cancer test, and has attached that release as Exhibit 99.1. The filing also notes that this report is incorporated by reference into Trinity Biotech’s existing registration statements on Form S-8.
Trinity Biotech plc filed a Form 6-K announcing two administrative updates. Shareholders approved amendments to the Company’s Constitution at the Annual General Meeting held on September 30, 2025. The Company and certain subsidiaries also executed an amendment to the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P.
The amended Constitution is filed as Exhibit 99.1, and the First Amendment to the Sixth Amended and Restated Credit Agreement and Guaranty, dated October 16, 2025, is filed as Exhibit 99.2. This Form 6-K is incorporated by reference into the Company’s existing Form S-8 registration statements.
Trinity Biotech reported breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, indicating a significant development in its product pipeline. The Form 6-K states the company issued a press release describing those trial results and filed it as Exhibit 99.1. The filing also discloses that on August 7, 2025 the company and certain subsidiaries amended and restated the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P. and that a warrant to purchase American Depositary Shares was issued in connection with that agreement. Copies of the press release, the Sixth Amended and Restated Credit Agreement and the warrant certificate are included as Exhibits 99.1, 99.2 and 99.3.
Trinity Biotech plc notified investors via Form 6-K that it issued a press release announcing the launch of an FDA-cleared Preeclampsia Testing Service. The company filed that press release as Exhibit 99.1 to the Form 6-K and stated the report is being incorporated by reference into its Form S-8 registration statements. The filing is signed by Chief Executive Officer John Gillard. The Form contains no financial results, pricing, partner or rollout details, and provides no operational or revenue metrics for the new service.
FAQ
What is the current stock price of Trinity Biotech Plc (TRIB)?
What is the market cap of Trinity Biotech Plc (TRIB)?
